- The approval is based on P-III trial assessing Wynzora Cream vs Taclonex Topical Suspension in 794 patients for the treatment of plaque psoriasis in adults 18 years of age or older
- The study resulted in a PGA treatment of 21.6% vs 14.6%, patients achieved at least a 4-point improvement in the peak pruritus NRS score at @4wks. 60.3% vs 21.4%
- Wynzora is a novel topical solution offering high efficacy, favorable safety and excellent and is filled for MAA application in EU
Click here to read full press release/ article | Ref: MC2 Therapeutics | Image: MC2 Therapeutics